Dmard

Patients with rheumatoid arthritis who previously had an inadequate response to biologic DMARDs demonstrated improved signs and symptoms after receiving daily doses of filgotinib, according to data published in JAMA.

In this video, John H. Stone, MD, MPH, professor of medicine at Harvard Medical School, the Edward A. Fox Chair in Medicine at Massachusetts General Hospital, discusses an important facet of IgG4-related disease other rheumatologists and providers should be aware of.